40th Annual J.P. Morgan Healthcare Conference Presentation

■ Financial Highlights 2021 Total revenue growth: 79%-82% Organic revenue growth: 65%-68% COVID-related revenue gains: O From ~$46M in 2020 to $175M-$180M in 2021 $200M+ COVID-related revenue anticipated for 2022 ■ Strong base business, +37% through Q3 2021, including growing contribution from gene therapy accounts Very strong order book going into 2022 R REPLIGEN 2021e figures above are based on 10/28/21 guidance YE 2021 ESTIMATES Revenue by Source BASE 67% COVID 27% M&A Gene Therapy 6% 15

View entire presentation